Jurcak; John G.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Jurcak; John G..The latest application filed is for "novel heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands".

Company Profile

0.11.11

Jurcak; John G. - Bethlehem PA
Jurcak; John G - Bethlehem PA
Jurcak; John G. - Bethelehem PA
Jurcak; John G. - Union City NJ
Jurcak; John G. - Somerset NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof Grant 7,777,042 - Kosley, Jr. , et al. August 17, 2	2010-08-17
Heterocyclic substituted carbonyl derivatives and their use as dopamine D.sub.3 receptor ligands Grant 7,772,252 - Hendrix , et al. August 10, 2	2010-08-10
Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands App 20090247509 - Hendrix; James A. ; et al.	2009-10-01
Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands Grant 7,550,469 - Hendrix , et al. June 23, 2	2009-06-23
Heterocyclic substituted carbonyl derivatives and their use as dopamine D.sub.3 receptor ligands Grant 7,521,445 - Hendrix , et al. April 21, 2	2009-04-21
Fkbp Binding Composition And Pharmaceutical Use Thereof App 20080139556 - KOSLEY; Raymond W. ; et al.	2008-06-12
Interleukin-4 Gene Expression Inhibitors App 20080132481 - ALKAN; Sefik S. ; et al.	2008-06-05
Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D.sub.4 antagonists Grant 7,253,165 - Shutske , et al. August 7, 2	2007-08-07
Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands App 20070161641 - Hendrix; James A. ; et al.	2007-07-12
Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands App 20070142351 - Hendrix; James A. ; et al.	2007-06-21
Heterocyclic substituted carbonyl derivatives and their use as dopamine D.sub.3 receptor ligands Grant 7,186,724 - Hendrix , et al. March 6, 2	2007-03-06
Indole derivatives as interleukin-4 gene expression inhibitors Grant 7,169,925 - Merriman , et al. January 30, 2	2007-01-30
Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d.sub.4 antagonists Grant 7,091,199 - Lee , et al. August 15, 2	2006-08-15
Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists App 20050107377 - Shutske, Gregory M. ; et al.	2005-05-19
Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands App 20050107389 - Hendrix, James A. ; et al.	2005-05-19
Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor App 20040220173 - Hendrix, James A. ; et al.	2004-11-04
Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands App 20040030137 - Hendrix, James A. ; et al.	2004-02-12
Indole derivatives as interleukin -4 gene expression inhibitors App 20040010029 - Merriman, Gregory H. ; et al.	2004-01-15
Interleukin-4 gene expression inhibitors App 20040006123 - Alkan, Sefik S. ; et al.	2004-01-08
3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related compounds Grant 5,229,388 - Hrib , et al. July 20, 1	1993-07-20
Benzoisothiazole- and benziosoxazole-3-carboxamides Grant 5,143,923 - Hrib , et al. September 1, 1	1992-09-01
3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles Grant 5,041,445 - Hrib , et al. August 20, 1	1991-08-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.